Aquatic Capital Management LLC Editas Medicine, Inc. Transaction History

Aquatic Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $115,995 - $182,655	16,500 New	16,500 $122,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $42,180 - $69,180	6,000 Added 352.94%	7,700 $56,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $139,776 - $221,928	-16,800 Reduced 90.81%	1,700 $15,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $156,864 - $250,518	12,900 Added 230.36%	18,500 $226,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $38,961 - $83,265	3,900 Added 229.41%	5,600 $66,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $23,936 - $46,971	1,700 New	1,700 $32,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.